# Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)

> **NCT00886769** · PHASE3 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 84 (actual)

## Conditions studied

- Systemic Juvenile Idiopathic Arthritis

## Interventions

- **DRUG:** Canakinumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00886769
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-07
- **Primary completion:** 2010-12
- **Final completion:** 2011-01
- **Target enrollment:** 84 (ACTUAL)
- **Why stopped:** recommendation by Data Monitoring Committee
- **Last updated:** 2017-03-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00886769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00886769, "Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT00886769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*